The primary hyperoxalurias are inborn errors of mefeatures of types I and II.
oxalate is excreted in the urine but is of low solubility uation, clinical management, and follow-up. Diagnosis of PHI and precipitates as a calcium salt. High urinary oxalate and PHII was made by hepatic enzyme analysis (N ϭ 11), increased urinary excretion of glycolate or glycerate (N ϭ 7), concentrations result in urolithiasis. Over time, renal or complete pyridoxine responsiveness (N ϭ 2). Six PHI and parenchymal damage caused by calcium oxalate deposifive PHII patients had measurements of calcium oxalate crystion leads to renal insufficiency, hyperoxalemia, and systalluria, urine supersaturation, and urine inhibition of calcium temic deposition of calcium oxalate. End-stage renal failoxalate crystal formation.
ure, metabolic bone disease, erythropoietin refractory
Results. PHI and PHII did not differ in age at the onset of anemia, skin ulcers, digital gangrene, cardiac arrhythsymptoms, initial serum creatinine, or plasma oxalate concentration. Urine oxalate excretion rates were higher in PHI (2.19 Ϯ mias, and cardiomyopathy reflect systemic oxalate depo-0.61 mmol/1.73 m 2 /24 hours) than PHII (1.61 Ϯ 0.43, P ϭ 0.04).
sition. Survival is poor with maintenance dialysis and in
Urine osmolality, calcium, citrate, and magnesium concentrapatients with extensive tissue oxalosis. Treatment stratetions were lower in PHI than PHII (P ϭ 0.001, P ϭ 0.019, P ϭ gies include pharmacologic doses of pyridoxine for pa-0.0002, P ϭ 0.03, respectively). Crystalluria scores and calcium tients with PHI responsive to this cofactor of alanine:glyoxalate inhibitory activity of the urine did not differ between oxylate aminotransferase and the use of agents such as PHI and PHII. Calcium oxalate supersaturation in the urine was less in PHI (7.3 Ϯ 1.9) compared with PHII (14.0 Ϯ 3.3, orthophosphate and citrate, which reduce calcium oxa-P ϭ 0.002). During follow-up of 10.3 Ϯ 9.6 years in PHI and late crystallization in the urine and in the renal paren- rate of 0.12 per million per year [9] . As of 1997 [10, 11] , only 24 patients with PHII had been described in the world literature, 8 of whom were identified during evalu-of the 24 patients had follow-up information available seven of the PHII patients because they were cared for as presumed PHI before PHII was described or prior to [11, 13, 15, 16] . It has been suggested that patients with PHII may have milder disease expression when comclinical availability of urine glycerate determinations and hepatic enzyme analysis. None of the PHII patients pared with PHI [11, 18] , although not all authors agree [19] hours to provide valid comparisons bereport. All eight of these excluded patients had PHI by tween children and adults [22] . Urine glycolate and hepatic enzyme analysis. Twelve PHI patients and seven l-glyceric acid were measured by gas chromatography PHII patients presented for initial evaluation with good [23] . The normal reference range for glycolate was 14 renal function, defined as a creatinine clearance of to 114 g/mg creatinine (21 to 168 mol/mmol creatigreater than or equal to 50 mL/min/1.73 m 2 . One PHII nine). The normal reference range for l-glyceric acid patient was studied one year after kidney only transwas 22 to 185 g/mg creatinine (24 to 198 mol/mmol plantation when her serum creatinine was 0.9 mg/dL. The creatinine). Enzyme studies of liver tissue were per-20 patients who underwent similar diagnostic evaluation, formed in the laboratories of Drs. C. Danpure and G. clinical management, and follow-up are the subjects of Rumsby [19, 24] . this report. All patients were cared for by one of the Eleven patients (6 with PHI and 5 with PHII) had authors. Partial information regarding some of the patients measurements of calcium oxalate crystalluria, calcium has been included in previous publications [4, 11, 18] .
oxalate supersaturation in urine, and inhibition of calOf the 12 patients with PHI, 6 were confirmed by cium oxalate crystal formation in urine. These studies hepatic enzyme analysis of the patient (3 patients) or an were obtained when the patients were not receiving medaffected sibling (3 patients) to have alanine:glyoxylate ications. After obtaining informed consent, patients were aminotransferase (AGT) deficiency. Four patients were admitted to the General Clinical Research Center for confirmed by increased urine glycolate and two patients three days while on their normal fluid intake and normal by complete pyridoxine responsiveness. Of the eight padiet. Reference values were obtained in 16 normal subtients with PHII, five patients from two unrelated families jects [7 women and 9 men; median age 31 years (range were confirmed by hepatic enzyme analysis of the patient 17 to 39 years)] who were unrelated to the patients. Two (2 patients) or an affected sibling (3 patients) to have consecutive 24-hour urine collections were obtained. deficiency of glyoxylate reductase or d-glycerate dehyEach voiding was collected in a beaker kept at 37ЊC. drogenase. The remaining three patients had high urine
The volume and pH of each sample were measured. A glycerate concentrations and normal glycolate.
2 mL aliquot of each voiding was filtered immediately For management of hyperoxaluria and stone disease, by vacuum through a 0.22 m Nucleopore filter (25 mm patients were instructed to drink eight ounces (a glass) diameter). The filter was then rinsed with four drops of of water every hour while awake and when up to void distilled water to remove traces of soluble salts and was during the night. Their usual diet was not changed. Sixair dried for crystal determination. Ten percent of each teen patients received both neutral phosphate and pyriurine voiding was placed under mineral oil for measuredoxine. Two patients received neutral phosphate alone ment of carbon dioxide, and 10% was stored with addition of 6N hydrochloric acid and the remainder in a pool. and two pyridoxine alone. Pyridoxine was prescribed to monium ion by the Berthelot technique; and carbon dioxide content by microgasometer. Crystalluria was assesed by the method of Werness using petrographic microscopy and scanning electron microscopy with energy dispersive x-ray spectroscopy [27]. Twenty-fourhour pooled collections were analyzed with a seeded crystal growth system to determine whether formation of calcium oxalate crystals was inhibited [28] . In this system, one inhibitor unit was defined arbitrarily as the concentration of inhibitor required for 50% reduction in the rate of crystal growth (k/k Ϫ k A ϭ 2) under standard conditions. Ionic strength, free ion activity, and supersaturation with calcium oxalate were estimated using Statistical analysis was by t-test for continuous variables and by chi square for nominal variables. Spearman correlation coefficients were used to compare the rates PHI than PHII, although the difference did not reach of decline in renal function. Kaplan-Meier survival perstatistical significance. The urinary concentrations of cicentages were used to compare the numbers of patients trate, calcium, and magnesium were lower in patients with progressing to end-stage renal disease during follow-up.
PHI compared with those with PHII (P ϭ 0.0002, P ϭ 0.019, and P ϭ 0.03, respectively). Urinary concentrations RESULTS of pyrophosphate, while lower in PH patients than normal Of the PHI patients, six were male, and six were fesubjects, did not differ between PHI and PHII. Calcium male. Among the PHII patients, one was male, and seven oxalate supersaturation of 7.3 Ϯ 1.9 in PHI and 14.0 Ϯ were female. The 12 patients with PHI were from 10 3.3 in PHII was higher than the 2.5 Ϯ 0.6 observed in unrelated families, and the 8 patients with PHII were control subjects (PHI vs. control P ϭ 0.04, PHII vs. control from 4 unrelated families. Initial clinical and laboratory P ϭ Ͻ 0.001). Calcium oxalate supersaturation was greater characteristics are displayed in Table 1 . No differences in PHII than PHI (P ϭ 0.002; Table 2 ). Crystal scores were found between PHI and PHII with regard to age were greater in PHI (2.7 Ϯ 1.4) and PHII (2.4 Ϯ 0.5) at onset of symptoms, age at diagnosis, nor initial serum compared with control subjects 0.6 Ϯ 0.7 (PHI vs. control creatinine. Twenty-four-hour creatinine clearance at ini-P ϭ 0.001, PHII vs. control P ϭ 0.00001), but did not tial assessment, while excellent in both groups, was lower differ between the PH subtypes. Calcium oxalate inhibiin PHI as compared with PHII (P ϭ 0.04). There was tion was significantly reduced in both PHI at 23.8 Ϯ 13.7 no difference between groups in plasma oxalate concenand PHII at 29.8 Ϯ 5.2 compared with control subjects trations nor fractional excretion of oxalate.
97 Ϯ 36 (PHI vs. control P ϭ 0.0001, PHII vs. control Urine oxalate excretion rates were higher in PHI than P ϭ 0.0002), but not different between subtypes. PHII (P ϭ 0.04; Fig. 1) . Urine findings are shown in Table
In the PHI and PHII groups combined, the 24-hour 2. Urine oxalate concentrations did not differ between urine oxalate excretion rate correlated inversely with the initial creatinine clearance (P ϭ 0.01). Urine citrate groups (P ϭ 0.41). Mean urine volume was higher in by patients reported in the literature [14] [15] [16] 30] . The explanation for more active stone formation and greater renal parenchymal damage in PHI compared DISCUSSION with PHII is suggested by the greater oxalate excretion Patients with PHI and PHII have increased urinary rates observed in PHI as well as by differences in urine calcium oxalate supersaturation, increased calcium oxacomposition. Oxalate excretion rates were inversely corlate crystalluria, and decreased urine inhibition of calrelated with renal clearance at initial evaluation (P ϭ cium oxalate crystal formation when compared with nor-0.01). In cell culture systems and in animal models, mal subjects, and they demonstrate a life-long propensity hyperoxaluria causes injury to renal tubular epithelial for urolithiasis. Our data confirm that patients with PHII cells, inducing proliferation and cell disruption [31] [32] [33] . have a more favorable long-term clinical course than
The interaction of calcium oxalate monohydrate crystals those with PHI. This difference was evident with regard and renal epithelial cells results in induction of genes to metabolic stone-forming activity, number of surgical encoding plasminogen activator inhibitor and plateletinterventions required for management of urolithiasis, derived growth factor (abstract; Hammes et al, J Am Soc and preservation of renal function. These differences Nephrol 5:864A, 1994), suggesting a pathophysiologic occurred despite a common management approach for mechanism for renal interstitial fibrosis in hyperoxaluric all patients with primary hyperoxaluria included in this states. Calcium oxalate crystals also can be demonstrated report. Although PHII appears less severe, the potential in renal interstitium [31, 33] . In humans, interstitial infor end-stage renal disease and systemic oxalate deposiflammation and interstitial fibrosis are reported in hyperoxaluria [34] [35] [36] [37] . tion remains. This possibility was reflected by our patient When compared with PHII, the PHI group had lower vation studies were not performed in the patients and concentrations of urinary citrate and magnesium. Both would be needed to address this observation further. It citrate and magnesium form complexes in urine, citrate is also possible that PHI patients, who had more frequent with calcium and magnesium with oxalate, reducing the symptomatic stone episodes, were more conscientious amount of oxalate and calcium available for precipitation regarding maintenance of a large oral fluid intake. [28] . Citrate also inhibits calcium oxalate crystal formation [28] . Whether the low concentrations of these inhibi-CONCLUSION tors in PHI result from metabolic differences is not clear Clinical characteristics such as age at onset of sympfrom these studies. However, our observations in other toms and age of diagnosis are not helpful in differentiat-PHI patients of persistently low urine citrate concentraing PHI from PHII. Furthermore, while there are differtions during periods of continued high urinary oxalate ences with regard to urine oxalate excretion rates and excretion following successful hepatic transplantation other urinary parameters, the overlap is such that these (unpublished data) suggest that the hypocitric aciduria values are not sufficient in an individual patient to differis not a result of the hepatic enzyme abnormality in PHI.
entiate between PHI and PHII. Urinary glycolate and Adsorption onto crystal surfaces as the cause of hypocitglycerate values and hepatic enzyme analysis are necesric aciduria is supported by our previous observation sary for accurate diagnosis. Advances in genetic testing that calcium oxalate inhibitory activity in the urine of PH may soon permit DNA analysis as an alternative [40, 41] . patients returns to normal when crystalluria decreases or
The finding of eight patients with PHII from four unredisappears with neutral phosphorus treatment [4] . lated families among our patients with primary hyperoxReduced urine citrate concentrations and reduced cialuria suggests that PHII may not be as rare as previously trate excretion could reflect renal tubulointerstitial injury resulting from high urine oxalate concentrations or thought. Our observations confirm that PHII follows a calcium oxalate crystals. Damage to renal tubular epithemore benign long-term clinical course than PHI. Differlium and interstitial inflammation have been reported in ences in metabolic production rates of oxalate and in hyperoxaluric patients [34, 38, 39] . The observed correlaurinary chemical composition may account, in part, for tion between urine citrate excretion and renal clearance this observation. Other factors remain to be evaluated. (P ϭ 0.02) is consistent with this hypothesis.
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